Pages that link to "Q36014004"

The following pages link to Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas (Q36014004):

Displaying 42 items.

• Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review (Q26785713) (← links)
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors (Q26828860) (← links)
• Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (Q27853224) (← links)
• International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma (Q28303718) (← links)
• Pulmonary adenocarcinoma: A renewed entity in 2011 (Q28395348) (← links)
• Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines (Q33411775) (← links)
• Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung (Q33531781) (← links)
• Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy (Q33599090) (← links)
• Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops (Q33769820) (← links)
• Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors (Q34103766) (← links)
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular (Q34159011) (← links)
• Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck (Q34159125) (← links)
• Field cancerization in non-small cell lung cancer: implications in disease pathogenesis (Q34272221) (← links)
• Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis (Q34308740) (← links)
• Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions (Q34568606) (← links)
• Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis (Q34809743) (← links)
• EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry (Q35164306) (← links)
• Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma (Q35176964) (← links)
• The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration (Q35208501) (← links)
• (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo. (Q35609644) (← links)
• Evolving Concepts in Lung Carcinogenesis (Q36178320) (← links)
• Preneoplasia of lung cancer (Q36190383) (← links)
• EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (Q36250691) (← links)
• Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy (Q36358309) (← links)
• Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancer (Q37029665) (← links)
• Personalizing lung cancer prevention through a reverse migration strategy (Q37080513) (← links)
• Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling (Q37175654) (← links)
• Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis (Q37334996) (← links)
• Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers (Q37438296) (← links)
• Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. (Q37628928) (← links)
• EGFR mutations and the terminal respiratory unit (Q37687922) (← links)
• Progressive Endobronchial Premalignancy: Marked by Original CIN (Q42958680) (← links)
• Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma. (Q48096086) (← links)
• An intermittent approach for cancer chemoprevention (Q51662524) (← links)
• Detecting EGFR alterations in clinical specimens-pitfalls and necessities. (Q53085284) (← links)
• Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma (Q53235626) (← links)
• Consistent mutation status within histologically heterogeneous lung cancer lesions. (Q54520483) (← links)
• A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. (Q54535177) (← links)
• [Recent progress in genetic variants associated with cancer and their implications in diagnostics development]. (Q64992147) (← links)
• Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis (Q84840731) (← links)
• Recent progress in genetic variants associated with cancer and their implications in diagnostics development (Q85033778) (← links)
• Rethink of EGFR in Cancer With Its Kinase Independent Function on Board (Q90053595) (← links)